Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a sell rating to a strong sell rating in a report published on Tuesday, BidAskClub reports.

A number of other equities research analysts have also recently commented on DCPH. ValuEngine cut Deciphera Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, April 9th. Piper Jaffray Companies raised their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an overweight rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. Canaccord Genuity dropped their target price on Deciphera Pharmaceuticals from $55.00 to $50.00 and set a buy rating on the stock in a research report on Friday, March 15th. Finally, Zacks Investment Research cut Deciphera Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, February 12th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $43.88.

Shares of DCPH opened at $23.16 on Tuesday. Deciphera Pharmaceuticals has a fifty-two week low of $18.55 and a fifty-two week high of $45.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.55 and a current ratio of 9.55.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Thursday, May 9th. The company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.41). Equities analysts forecast that Deciphera Pharmaceuticals will post -4.57 earnings per share for the current fiscal year.

In other news, CFO Thomas Patrick Kelly sold 2,100 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $25.20, for a total transaction of $52,920.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 17,073 shares of company stock worth $399,388 over the last 90 days. Insiders own 7.02% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its stake in Deciphera Pharmaceuticals by 17.7% in the third quarter. Bank of New York Mellon Corp now owns 66,408 shares of the company’s stock valued at $2,571,000 after buying an additional 9,966 shares during the period. Vanguard Group Inc. lifted its stake in Deciphera Pharmaceuticals by 2.1% in the third quarter. Vanguard Group Inc. now owns 675,517 shares of the company’s stock valued at $26,156,000 after buying an additional 14,081 shares during the period. Rhumbline Advisers lifted its stake in Deciphera Pharmaceuticals by 53.6% in the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock valued at $241,000 after buying an additional 4,000 shares during the period. BlackRock Inc. lifted its stake in Deciphera Pharmaceuticals by 73.6% in the fourth quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock valued at $24,625,000 after buying an additional 497,427 shares during the period. Finally, Citigroup Inc. lifted its stake in Deciphera Pharmaceuticals by 197.4% in the fourth quarter. Citigroup Inc. now owns 73,598 shares of the company’s stock valued at $1,545,000 after buying an additional 48,850 shares during the period. 58.89% of the stock is currently owned by hedge funds and other institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Read More: What is an SEC Filing?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.